Literature DB >> 18614922

The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation.

Evguenia S Svarovskaia1, Joy Y Feng, Nicolas A Margot, Florence Myrick, Derrick Goodman, John K Ly, Kirsten L White, Nilima Kutty, Ruth Wang, Katyna Borroto-Esoda, Michael D Miller.   

Abstract

BACKGROUND: The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase can be selected by abacavir, didanosine, tenofovir, and stavudine in vivo resulting in reduced susceptibility to these drugs and decreased viral replication capacity. In clinical isolates, K65R is frequently accompanied by the A62V and S68G reverse transcriptase mutations.
METHODS: The role of A62V and S68G in combination with K65R was investigated using phenotypic, viral growth competition, pre-steady-state kinetic, and excision analyses.
RESULTS: Addition of A62V and S68G to K65R caused no significant change in human immunodeficiency virus type 1 resistance to abacavir, didanosine, tenofovir, or stavudine but partially restored the replication defect of virus containing K65R. The triple mutant K65R+A62V+S68G still showed some replication defect compared with wild-type virus. Pre-steady-state kinetic analysis demonstrated that K65R resulted in a decreased rate of incorporation (kpol) for all natural dNTPs, which were partially restored to wild-type levels by addition of A62V and S68G. When added to K65R and S68G, the A62V mutation seemed to restore adenosine triphosphate-mediated excision of tenofovir to wild-type levels.
CONCLUSIONS: A62V and S68G serve as partial compensatory mutations for the K65R mutation in reverse transcriptase by improving the viral replication capacity, which is likely due to increased incorporation efficiency of the natural substrates.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18614922     DOI: 10.1097/QAI.0b013e31817bbe93

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  28 in total

1.  Evolution of drug-resistant viral populations during interruption of antiretroviral therapy.

Authors:  Dongning Wang; Charles B Hicks; Neela D Goswami; Emi Tafoya; Ruy M Ribeiro; Fangping Cai; Alan S Perelson; Feng Gao
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

Review 2.  The high cost of fidelity.

Authors:  Sarah B Lloyd; Stephen J Kent; Wendy R Winnall
Journal:  AIDS Res Hum Retroviruses       Date:  2014-01       Impact factor: 2.205

3.  A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses.

Authors:  Anna N Kolomeets; Vici Varghese; Philippe Lemey; Marina R Bobkova; Robert W Shafer
Journal:  AIDS       Date:  2014-11-13       Impact factor: 4.177

4.  Reduced viral fitness and lack of cross-class resistance with integrase strand transfer inhibitor and nucleoside reverse transcriptase inhibitor resistance mutations.

Authors:  Kristen N Andreatta; Derrick D Goodman; Michael D Miller; Kirsten L White
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

5.  A cell-based strategy to assess intrinsic inhibition efficiencies of HIV-1 reverse transcriptase inhibitors.

Authors:  Michael E Abram; Manuel Tsiang; Kirsten L White; Christian Callebaut; Michael D Miller
Journal:  Antimicrob Agents Chemother       Date:  2014-11-17       Impact factor: 5.191

6.  Human Immunodeficiency Virus Type 1 Drug Resistance Mutations Update.

Authors:  Robert W Shafer
Journal:  J Infect Dis       Date:  2017-12-01       Impact factor: 5.226

7.  Drug Susceptibility and Viral Fitness of HIV-1 with Integrase Strand Transfer Inhibitor Resistance Substitution Q148R or N155H in Combination with Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Resistance Substitutions.

Authors:  Kristen N Andreatta; Michael D Miller; Kirsten L White
Journal:  Antimicrob Agents Chemother       Date:  2015-11-16       Impact factor: 5.191

8.  Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.

Authors:  Michael E Abram; Rebecca M Hluhanich; Derrick D Goodman; Kristen N Andreatta; Nicolas A Margot; Linda Ye; Anita Niedziela-Majka; Tiffany L Barnes; Nikolai Novikov; Xiaowu Chen; Evguenia S Svarovskaia; Damian J McColl; Kirsten L White; Michael D Miller
Journal:  Antimicrob Agents Chemother       Date:  2013-03-25       Impact factor: 5.191

9.  The Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance.

Authors:  Antonio J Acosta-Hoyos; Walter A Scott
Journal:  Viruses       Date:  2010-01-28       Impact factor: 5.048

10.  Structural basis for the role of the K65R mutation in HIV-1 reverse transcriptase polymerization, excision antagonism, and tenofovir resistance.

Authors:  Kalyan Das; Rajiv P Bandwar; Kirsten L White; Joy Y Feng; Stefan G Sarafianos; Steven Tuske; Xiongying Tu; Arthur D Clark; Paul L Boyer; Xiaorong Hou; Barbara L Gaffney; Roger A Jones; Michael D Miller; Stephen H Hughes; Eddy Arnold
Journal:  J Biol Chem       Date:  2009-10-07       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.